A population-based study suggests that the prevalence is less than 2% of all “demyelinating” disease in the U.S.
Neuromyelitis optica (NMO) and NMO-spectrum disorder (NMOSD) are uncommon in the U.S., although epidemiologic studies are lacking. This population-based study evaluated the prevalence of NMO/NMOSD and the seroprevalence of aquaporin-4 (AQP4) immunoglobulin G (IgG) positivity in Olmsted County, Minnesota, and in Martinique, French West Indies. All cases of inflammatory demyelinating disease (IDD) were evaluated by the Rochester Epidemiology Project and a Martinique population health registry.
Blood samples were available from 84% of the 434 IDD cases within Olmstead County and 81% of the 237 cases in Martinique. Six cases of NMO/NMOSD were identified within the 434 IDD cases within Olmsted County, and 39 cases were identified within the 237 I…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)